scbmtБИОМЕДИЦИНАJournal Biomed2074-59822713-0428Scientific center of biomedical technologies of Federal Medical and Biological Agency10.33647/2074-5982-16-4-24-33scbmt-1215Research ArticleРЕЛЕВАНТНОЕ И АЛЬТЕРНАТИВНОЕ БИОМОДЕЛИРОВАНИЕRELEVANT AND ALTERNATIVE BIOMODELLINGМодель фатального острого поражения легких и острого респираторного дистресс-синдромаA Model of Fatal Acute Lung Injury and Acute Respiratory Distress SyndromeПомыткинИ. А.PomytkinI. A.

Помыткин Игорь Анатольевич, к.х.н.

143442, Московская обл., Красногорский р-н, п. Светлые горы, владение 1

Igor A. Pomytkin, Cand. Sci. (Chem.)

143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1

ipomytkin@mail.ruКаркищенкоВ. Н.KarkischenkoV. N.

Каркищенко Владислав Николаевич, д.м.н., проф.

143442, Московская обл., Красногорский р-н, п. Светлые горы, владение 1

Vladislav N. Karkischenko, Dr. Sci. (Med.), Prof.

143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1

scbmt@yandex.ruФокинЮ. В.FokinYu. V.

Фокин Юрий Владимирович, к.б.н.

143442, Московская обл., Красногорский р-н, п. Светлые горы, владение 1

Yuriy V. Fokin, Cand. Sci. (Biol.)

143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1

fokin@scbmt.ruНестеровМ. С.NesterovM. S.

Нестеров Максим Сергеевич

143442, Московская обл., Красногорский р-н, п. Светлые горы, владение 1

Maxim S. Nesterov

143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1

mdulya@gmail.comПетроваН. В.PetrovaN. V.

Петрова Наталья Владимировна

143442, Московская обл., Красногорский р-н, п. Светлые горы, владение 1

Nataliya V. Petrova

143442, Moscow region, Krasnogorsk district, Svetlye gory village, building 1

m-sklad@yandex.ruФГБУН «Научный центр биомедицинских технологий Федерального медико-биологического агентства России»РоссияScientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of RussiaRussian Federation2020161020201642433Copyright © Помыткин И.А., Каркищенко В.Н., Фокин Ю.В., Нестеров М.С., Петрова Н.В., 20202020Помыткин И.А., Каркищенко В.Н., Фокин Ю.В., Нестеров М.С., Петрова Н.В.Pomytkin I.A., Karkischenko V.N., Fokin Y.V., Nesterov M.S., Petrova N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.scbmt.ru/jour/article/view/1215

Настоящая работа посвящена разработке экспериментальной фатальной модели острого поражения легких и острого респираторного дистресс-синдрома (ОРДС) на мышах линии C57Bl/6Y. Модель основана на интратрахеальном введении бактериального липополисахарида (ЛПС) с добавлением иммуномодуляторов мурамилпептида и полного адъюванта Фрейнда мышам, предварительно сенсибилизированным α-галактозилцерамидом. Модель характеризуется диффузным альвеолярным поражением легких, высокой летальностью, многократным повышением мРНК и белка интерлейкина-6 в тканях легкого и может быть использована для оценки эффективности потенциальных средств лечения острого поражения легких и острого респираторного дистресс-синдрома, в т. ч. воспроизводящего существенные признаки ОРДС при COVID-19.

This study was aimed at developing an experimental model of fatal acute lung injury and acute respiratory distress syndrome (ARDS) based on the intratracheal administration of bacterial lipopolysaccharide (LPS) in combination with muramylpeptide and Freund’s complete adjuvant to C57Bl/6Y mice sensitized with α-galactosylceramide. The developed model is characterized by diffuse alveolar damage to the lungs and high mortality rates, as well as by a multifold increase in the mRNA level of interleukin-6 in the lungs. The model can be used for assessing the efficacy of drug candidates in the treatment of acute lung injury and ARDS, including in COVID-19.

острое поражение легкихострый респираторный дистресс-синдроммыши линии C57Bl/6Y«цитокиновый шторм»интерлейкин-6COVID-19acute lung injuryacute respiratory distress syndromeC57Bl/6Y mice line“cytokine storm”interleukin-6COVID-19ReferencesКаркищенко Н.Н. Альтернативы биомедицины. Т. 1. Основы биомедицины и фармакомоделирования. М.: Изд-во ВПК, 2007. 320 с.Karkischenko N.N. Al’ternativy biomediciny. T. 1. Osnovy biomediciny i farmakomodelirovaniya [Biomedicine alternatives. Vol. 1. Fundamentals of biomedicine and pharmaco-modeling]. Moscow: Izdatel’stvo VPK, 2007. 320 p. (In Russian).Каркищенко Н.Н. Основы биомоделирования. М.: Межакадемическое изд-во ВПК, 2004. 607 с.Karkischenko N.N. Osnovy biomodelirovaniya [Basics of biomodeling]. Moscow: Mezhakademicheskoye Izdatel’stvo VPK, 2004. 607 p. (In Russian).Руководство по лабораторным животным и альтернативным моделям в биомедицинских исследованиях / Под ред. Н.Н. Каркищенко и др. М.: Профиль-2С, 2010. 358 p.Rukovodstvo po laboratornym zhivotnym i al’ternativnym modelyam v biomedicinskih issledovaniyah [Manual on laboratory animals and alternative models in biomedical research]. Ed. by N.N. Karkischenko, et al. Moscow: Profil’-2S Publ., 2010. 358 p. (In Russian).Aoyagi T., Yamamoto N., Hatta M., Tanno D., Miyazato A., Ishii K., et al. Activation of pulmonary invariant NKT cells leads to exacerbation of acute lung injury caused by LPS through local production of IFN-γ and TNF-α by Gr-1+ monocytes. Int. Immunol. 2011;23(2):97–108.Aoyagi T., Yamamoto N., Hatta M., Tanno D., Miyazato A., Ishii K., et al. Activation of pulmonary invariant NKT cells leads to exacerbation of acute lung injury caused by LPS through local production of IFN-γ and TNF-α by Gr-1+ monocytes. Int. Immunol. 2011;23(2):97–108.Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., et al. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res. 2015;48(5):427–432.Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., et al. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res. 2015;48(5):427–432.Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P., et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072.Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P., et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072.Crosby C.M., Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat. Rev. Immunol. 2018;18(9):559–574.Crosby C.M., Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat. Rev. Immunol. 2018;18(9):559–574.D’Alessio F.R. Mouse Models of Acute Lung Injury and ARDS. Methods Mol. Biol. 2018;1809:341–350.D’Alessio F.R. Mouse Models of Acute Lung Injury and ARDS. Methods Mol. Biol. 2018;1809:341–350.Davey R.T. Jr., Lynfield R., Dwyer D.E., Losso M.H., Cozzi-Lepri A., Wentworth D., et al. INSIGHT FLU 002 & 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One. 2013;8(2):e57121.Davey R.T. Jr., Lynfield R., Dwyer D.E., Losso M.H., Cozzi-Lepri A., Wentworth D., et al. INSIGHT FLU 002 & 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One. 2013;8(2):e57121.Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24.Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24.Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020;58(7):1021–1028.Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020;58(7):1021–1028.Kudo D., Toyama M., Aoyagi T., Akahori Y., Yamamoto H., Ishii K., et al. Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. Clin. Exp. Immunol. 2013;173(2):276–287.Kudo D., Toyama M., Aoyagi T., Akahori Y., Yamamoto H., Ishii K., et al. Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. Clin. Exp. Immunol. 2013;173(2):276–287.Liu T., Zhang L., Joo D., Sun S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017;2. DOI: 10.1038/sigtrans.2017.23.Liu T., Zhang L., Joo D., Sun S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017;2. DOI: 10.1038/sigtrans.2017.23.McGonagle D., Sharif K., O’Regan A., Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020;19(6):102537.McGonagle D., Sharif K., O’Regan A., Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020;19(6):102537.Ogawa C., Liu Y.J., Kobayashi K.S. Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr. Bioact. Compd. 2011;7(3):180–197.Ogawa C., Liu Y.J., Kobayashi K.S. Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr. Bioact. Compd. 2011;7(3):180–197.Potey P.M., Rossi A.G., Lucas C.D., Dorward D.A. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. J. Pathol. 2019;247(5):672–685.Potey P.M., Rossi A.G., Lucas C.D., Dorward D.A. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. J. Pathol. 2019;247(5):672–685.Rincon M., Irvin C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci. 2012;8(9):1281–1290.Rincon M., Irvin C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci. 2012;8(9):1281–1290.Zhao J., Li X., Gao Y., Huang W. Risk factors for the exacerbation of patients with 2019 Novel Coronavirus: A meta-analysis. Int. J. Med. Sci. 2020;17(12):17441750.Zhao J., Li X., Gao Y., Huang W. Risk factors for the exacerbation of patients with 2019 Novel Coronavirus: A meta-analysis. Int. J. Med. Sci. 2020;17(12):17441750.

The authors declare that there are no conflicts of interest present.